By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Kadmon Corporation (Formerly Known As Kadmon Pharmaceuticals) 

Alexandria Center for Life Sciences
450 East 29th Street, 5th Floor
New York  New York  10016  U.S.A.
Phone: 212-308-6000 Fax: n/a




Company News
Kadmon Presents Preclinical Data Supporting The Therapeutic Potential Of ROCK Inhibition In Pulmonary Fibrosis 3/28/2017 8:40:20 AM
Kadmon Reports Upcoming Milestones And Fourth Quarter And Full Year 2016 Financial Results 3/23/2017 6:53:16 AM
Kadmon Announces Approximately $23 Million Equity Financing 3/8/2017 7:55:25 AM
Kadmon Submits Abbreviated New Drug Application Filing For Trientine Hydrochloride To FDA 12/6/2016 11:35:35 AM
Kadmon Presents Encouraging Data On Tesevatinib In EGFR-Mutated Non-Small Cell Lung Cancer With Brain Metastases And/Or Leptomeningeal Metastases 12/6/2016 8:49:37 AM
Kadmon To Present Additional Data Demonstrating Tesevatinib Safety For The Treatment Of Polycystic Kidney Disease At American Society of Nephrology Kidney Week 2016 11/21/2016 12:45:42 PM
Q3 Report Reveals Kadmon Has Quietly Reduced 15% of Workforce Since July 9/23/2016 10:11:51 AM
Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 In Chronic Graft-Versus Host Disease 9/22/2016 12:05:15 PM
Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 In Psoriasis 9/22/2016 12:02:05 PM
Kadmon Reports Financial And Operational Results For The Three And Six Months Ended June 30, 2016 9/8/2016 10:55:56 AM